Neoplastic Proliferations of White Cells

~ Myeloid Neoplasms III

Ghadeer AlMuhaisen, M.D. Consultant hematopathologist Mutah University

Essential Thrombocythemia (ET)


- Megakaryocyte proliferation with overproduction of platelets.
- Elevated platelet counts (>600x10^{×9}/L).
- Separated from PCV and primary myelofibrosis based on the absence of polycythemia and marrow fibrosis, respectively.

Essential Thrombocythemia – Pathogenesis

- ET is associated with activating point mutations in JAK2 (50%), a receptor tyrosine kinase that is normally activated by thrombopoietin.
- Constitutive JAK2 renders the progenitor <u>thrombopoietin-</u> independent and leads to hyperproliferation.
- The JAK2 mutation is the same as that found in almost all cases of PCV.
- ▶ Why some patients with JAK2 mutations present with PCV & others with ET → not understood.


Essential Thrombocythemia – Morphology

Bone marrow cellularity is usually only mildly increased, but megakaryocytes are often markedly increased in number with abnormal large forms.



Essential Thrombocythemia – Morphology

Peripheral smears usually reveal abnormally large platelets often accompanied by mild leukocytosis.



ET- Clinical features

- ET is an indolent disorder with long asymptomatic periods
 Only occasional thrombotic or hemorrhagic crises.
- ET manifests clinically with elevated platelet counts.
- Causes of reactive thrombocytosis, (such as inflammatory disorders & iron deficiency) must be excluded before the diagnosis can be established

ET- Clinical features

- Platelets are not only increased in numbers but also frequently demonstrate qualitative abnormalities in functional tests.
- The types of thrombotic events resemble those observed in PCV.
- ▶ A characteristic symptom → erythromelalgia, a throbbing and burning of hands and feet caused by occlusion of small arterioles by platelet aggregates → may also be seen in PCV.

- ▶ Median survival times → 12~15years
- Transformation to myelofibrosis (spent phase) is uncommon.
- Transformation to acute leukemia is rare.

Primary Myelofibrosis (PM)

- ► The hallmark of primary myelofibrosis is the development of **obliterative** marrow fibrosis → reduces bone marrow hematopoiesis →
- 1) Cytopenias.
- 2) Extensive extramedullary hematopoiesis.
- Histologically, the appearance is identical to the spent phase that occurs occasionally late in the course of other MPN.

PM - Pathogenesis


- JAK2 mutations are present in 50% to 60% of cases
- Why JAK2 mutations are associated PCV in some patients & PM in others is not understood.

PM - Pathogenesis

- Pathogenesis is similar between PM and spent phase MPN
- The characteristic marrow fibrosis is caused by the inappropriate release of **fibrogenic factors** from neoplastic **megakaryocytes.**
- Two factors synthesized by megakaryocytes have been implicated (fibrogenic factors):
- 1) Platelet-derived growth factor (PDGF).
- **2)** TGF-β. (collagen deposition and angiogenesis)

- ▶ PB smear is markedly abnormal →Leukoerythroblastosis
- Red cells often exhibit bizarre shapes (poikilocytes, teardrop cells)
- 2) Nucleated erythroid precursors.
- 3) Immature white cells (myelocytes and metamyelocytes).
- Along with abnormal large platelets.


PB smear showing 2 nucleated RBCs (red), 2 tear drop RBCs (black) and a myelocyte (blue)



+BM in advanced cases is hypocellular & diffusely fibrotic.

+ In early cases it may be hypercellular & only focal fibrosis.

+Abnormally large and clustered megakaryocytes.



PM - Clinical Features

- Age more than 60
- Anemia and splenomegaly.
- Fatigue, weakness and night sweats
- Lab results; normochromic and normocytic anemia and Leukoerythroblatosis
- Bone marrow is essential for the diagnosis.

PM - Prognosis

- Median survival is 4-5 years.
- ▶ 5-20% transform to AML.
- More difficult to treat than PCV and CML.
- Treat with JAK2 inhibitors and HSCT.

Dysplasia in Myelodysplastic Syndrome

Dysgranulopoiesis



segmented neutrophil

Dyserythropoiesis





Pseudo-Pelger-Hüet anomaly







Macrocytosis Chromatin Hypo-, agranulation Asynchr. maturation clumping of cytoplasm nucleus - cytoplasm



Macrocytic / megaloblastic changes

Normal erythroblast

Dysmegakaryopoiesis

Normal

megakaryocyte

Nuclear bridging

Separated single

Nuclei

Nuclear lobulation

Mikromega-

"

karyocyte

Multiple nuclei

Cytoplasmic granules

megakaryocyte







Small binucleated megakaryocyte

Cantú Rajnoldi et al. Ann Hematol 2005;84:429-33

Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

18

A group of clonal stem cell disorders characterized by maturation defects that are associated with ineffective hematopoiesis with cytopenias and a high <u>risk of</u> <u>transformation to AML.</u>

Myelodysplastic Syndromes (MDS)

- BM is replaced by the clonal transformed multipotent stem cell that retains the capacity to differentiate into red cells, granulocytes, and platelets, <u>but in an ineffective &</u> <u>disordered fashion. (cells stay in the BM)</u>
- So; BM is hypercellular or normocellular, but the PB shows one or more cytopenias.
- The abnormal cells in BM are genetically unstable & prone to the acquisition of additional mutations -> transformation to AML.


MDS - Pathogenesis

- Most cases are idiopathic, but some develop after exposure to carcinogens, previous cancer therapy, chemotherapy with alkylating agents or ionizing radiation therapy.
- ~10% of MDS have loss-of-function mutations in tumorsuppressor gene TP53 -> often associated with chromosomal instability.
- Which is correlated with complex karyotype and poor clinical outcomes

- Hypercellular bone marrow.
- Dysplastic changes
- Erythroid: Abnormal nuclear contour and iron deposits (ring sideroblasts)
- 2) Myeloid: abnormal segmentation and granulation
- 3) Megakaryocyte: single nuclear lobes or multiple separate nuclei.




Erythroid: Abnormal nuclear abnormalities & <u>iron deposits</u> (<u>ring sideroblasts</u>)






Myeloid: abnormal segmentation; **Pseudo-Pelger-Hüet cells,** neutrophils with only two nuclear lobes



Megakaryocyte: single nuclear lobes or multiple separate nuclei (pawn ball megakaryocytes)





MDS – Clinical features

- Predominantly a disease of older adults, 70s
- Up to half of cases \rightarrow discovered incidentally.
- ▹ If symptomatic, it presents with weakness, infections, and hemorrhages → all due to pancytopenia.
- Poor response to conventional chemotherapy.
- ▶ Transformation to AML \rightarrow in 10-40% (rapid in t-MDS)
- Prognosis is variable.
- Median survival time ranges from 9 to 29 months.

PRESENTATION OF THE ANTIGEN



THE CYSTEINE CHAPEL